Voluloride(Voluloride) - 药物靶点：ENaC_在研适应症：干眼症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

+ [1]

靶点

ENaC

作用方式

阻滞剂

作用机制

ENaC阻滞剂(上皮细胞钠离子通道阻滞剂)

治疗领域

眼部疾病

在研适应症

干眼症

非在研适应症-

原研机构

Parion Sciences, Inc.

在研机构

Parion Sciences, Inc.Shire Pharmaceuticals Services Ltd.

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C38H67ClN18O4

InChIKeyOKBDJMKISGUWNG-VSGBNLITSA-N

CAS号1498299-91-4

关联

3

项与 Voluloride 相关的临床试验

NCT02831387

/ Terminated临床2期

Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Assessing Safety and Efficacy Over 28 Days

The purpose of this study is to evaluate the effect of treatment with 0.017% P-321 on Dry Eye Symptoms.

开始日期2016-07-01

申办/合作机构

Parion Sciences, Inc.

NCT02824913

/ Terminated临床2期

Randomized, Crossover Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Characterized by Low Tear Volume

The purpose of this Phase 2a study is to assess changes in tear volume by the non-invasive techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 Ophthalmic Solution or Placebo in subjects with tear deficient dry eye disease.

开始日期2016-07-01

申办/合作机构

Parion Sciences, Inc.

NCT02242032

/ Completed临床1期

A Double-Masked, Randomized, Placebo-Controlled Dose Escalation Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

The purpose of this study is to assess the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye disease.

开始日期2014-07-01

申办/合作机构

Parion Sciences, Inc.

100 项与 Voluloride 相关的临床结果

登录后查看更多信息

100 项与 Voluloride 相关的转化医学

登录后查看更多信息

100 项与 Voluloride 相关的专利（医药）

登录后查看更多信息

1

项与 Voluloride 相关的文献（医药）

2012-09-01·Scandinavian Journal of Immunology4区 · 医学

A Novel Cytotoxic T lymphocyte Epitope Analogue with Enhanced Activity Derived From Cyclooxygenase‐2

4区 · 医学

Article

作者: Y. M. Qi ; M. X. Zhai ; Y. J. He ; M. Sun ; Y. H. Wu ; X. Chen ; R. R. Shi ; W. J. Zhai ; Y. F. Gao ; Z. Y. Wu

AbstractCyclooxygenase‐2 is a promising target for cancer immunotherapy. Here, we designed the analogues p321‐9L and p321‐1Y9L (YLIGETIKL) from cyclooxygenase‐2‐derived native peptide p321. Then, we tested the binding affinity and stability of the analogues and their ability to elicit specific immune response both in vitro (from PBMCs of HLA‐A*02+ healthy donors) and in vivo (from HLA‐A2.1/Kb transgenic mice). Our results indicated that the activity of cytotoxic T lymphocytes induced by p321‐9L and p321‐1Y9L was more potent than that of p321. In conclusion, the epitope analogue, especially p321‐1Y9L, may be a good candidate which could be used to the immunotherapy of patients with tumours expressing cyclooxygenase‐2.

100 项与 Voluloride 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干眼综合征	临床2期	美国	Parion Sciences, Inc.	2016-07-01
干眼症	临床2期	-	Shire Pharmaceuticals Services Ltd.	-
干眼症	临床2期	-	Parion Sciences, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02831387 (CTgov)	临床2期	干眼综合征	47	P-321 Ophthalmic Solution	網鏇壓壓醖膚壓網願鬱(鬱壓觸蓋觸蓋憲選鹽鏇) = 簾鬱窪膚築範鏇蓋網窪憲壓壓餘鹽夢壓鹹膚糧 (襯遞鏇顧鏇製襯顧廠憲, 廠構壓範顧鏇鹹廠顧製 ~ 觸壓艱膚願衊齋繭願蓋) 更多	-	2018-10-11
NCT02824913 (CTgov)	临床2期	干眼综合征	1	P-321 Ophthalmic Solution (P-321 Ophthalmic Solution)	鏇簾遞蓋糧鹽壓窪廠鬱(襯鹽築襯鏇鬱鑰構憲繭) = 衊鹹醖糧齋鹹範積觸範齋鹹積襯餘獵觸製蓋獵 (願餘艱壓艱齋製鏇艱艱, 蓋夢餘積構願築遞鏇膚 ~ 遞夢顧膚醖簾憲窪顧襯) 更多	-	2018-01-19
NCT02824913 (CTgov)	临床2期	干眼综合征	1	P-321 Ophthalmic Solution placebo (Drug: P-321 Ophthalmic Solution Placebo)	鏇簾遞蓋糧鹽壓窪廠鬱(襯鹽築襯鏇鬱鑰構憲繭) = 製憲鬱窪衊蓋齋醖膚淵齋鹹積襯餘獵觸製蓋獵 (願餘艱壓艱齋製鏇艱艱, 觸範遞窪壓餘簾窪鹹觸 ~ 夢範淵廠繭蓋壓壓淵選) 更多	-	2018-01-19
ARVO2014	N/A	-	-	P-321 0.1%	(鬱鹽鏇鏇遞鬱膚糧願鹽) = increased slightly during multiple dose administration reaching steady state levels by Day 4 衊簾餘願願壓糧網選衊 (鑰醖獵齋製襯衊餘獵選 ) 更多	-	2014-04-01